指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

未来医院获得性/呼吸机相关性细菌性肺炎抗菌治疗临床试验疗效评价的共识临床终点细化

Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.
指南 / 共识 · Clin Infect Dis · 2019-01-01
一句话结论国际专家共识采用Delphi法推荐:VABP用28天生存、28天无机械通气天数、7-10天临床治愈的层次复合终点;HABP用28天生存和7-10天临床治愈的层次复合终点。

该共识针对医院获得性肺炎(HABP)和呼吸机相关性肺炎(VABP)随机临床试验中终点异质性问题,由26名国际重症、感染病及制药行业专家通过Delphi法投票。推荐VABP采用层次复合终点:28天生存、28天无机械通气天数、7-10天临床治愈;HABP采用28天生存和7-10天临床治愈。临床治愈定义为入组时体征症状缓解且影像学改善或无进展。超过70%专家同意评估28天生存和无机械通气天数以及治疗开始后7-10天临床治愈,层次顺序经3轮Delphi达成72%共识。

要点

  • VABP临床试验推荐层次复合终点:第一优先28天生存,第二优先28天无机械通气天数,第三优先7-10天临床治愈。
  • HABP临床试验推荐层次复合终点:第一优先28天生存,第二优先7-10天临床治愈。
  • 临床治愈定义为入组时存在的体征和症状缓解,且影像学征象改善或无进展。
  • 超过70%专家同意评估28天生存、28天无机械通气天数及治疗开始后7-10天临床治愈。
  • 终点各成分的层次顺序经3轮Delphi投票达成72%共识。

适用人群与场景

  • 未来评估抗菌治疗疗效的HABP/VABP临床试验人群。

诊断标准与关键阈值

  • 临床治愈:入组时存在的体征和症状缓解,且影像学征象改善或无进展。
  • VABP复合终点成分:28天生存、28天无机械通气天数、7-10天临床治愈。
  • HABP复合终点成分:28天生存、7-10天临床治愈。

研究设计与关键结果

  • 26名来自重症医学、感染病学和制药行业的国际专家采用Delphi法进行投票。
  • 专家组推荐VABP采用层次复合终点,按优先顺序为:28天生存、28天无机械通气天数、7-10天临床治愈。
  • 专家组推荐HABP采用层次复合终点,按优先顺序为:28天生存、7-10天临床治愈。
  • 超过70%的专家同意评估28天生存、28天无机械通气天数以及治疗开始后7-10天临床治愈。
  • 终点成分的层次顺序经3轮Delphi投票达成72%共识。

证据类型、等级与局限

  • 证据类型:国际专家共识(Delphi法)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.

METHODS: Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method.

RESULTS: The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free days through day 28, and (3) clinical cure between study days 7 and 10 for VABP; and (1) survival (day 28) and (2) clinical cure (days 7-10) for HABP. Clinical cure was defined as the combination of resolution of signs and symptoms present at enrollment and improvement or lack of progression of radiological signs. More than 70% of the experts agreed to assess survival and mechanical ventilation-free days though day 28, and clinical cure between day 7 and day 10 after treatment initiation. Finally, the hierarchical order of endpoint components was reached after 3 Delphi rounds (72% agreement).

CONCLUSIONS: We provide a multinational expert consensus on separate hierarchical composite endpoints for VABP and HABP, and on a definition of clinical cure that could be considered for use in future HABP/VABP clinical trials.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

参考来源

  1. Weiss E, Zahar JR, Alder J, et al. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clin Infect Dis. 2019. PMID: 30722013. doi:10.1093/cid/ciz093

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。